Q3 Earnings Forecast for Neurogene Issued By Leerink Partnrs

Neurogene Inc. (NASDAQ:NGNE – Free Report) – Leerink Partnrs reduced their Q3 2025 EPS estimates for shares of Neurogene in a note issued to investors on Monday, August 11th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1.18) per share for the quarter, down from their prior estimate of ($1.14). The […]

Leave a Reply

Your email address will not be published.

Previous post CAB Payments (LON:CABP) Receives House Stock Rating from Shore Capital
Next post HC Wainwright Lifts Earnings Estimates for Nuvectis Pharma